Alpine Immune Sciences, Inc. (the “Company”) (NASDAQ: ALPN) is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. The Company is seeking to create first or best-in-class multifunctional immunotherapies via its unique protein engineering technologies to improve outcomes in patients with serious diseases.